Delix Therapeutics closes $100M Series C in oversubscribed round led by JJDC and DDF

Oversubscribed $100M Series C supports Delix’s neuroplastogen programs and clinical development with lead investors JJDC and DDF.

AI-assisted, human-published

Latest headlines

Join us for funding and investment opportunities.

Stay connected!

If you have a serious, bonafide inquiry into the VentureCapital.com or PrivateEquity.com domain names, please contact us here